Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News BioNxt Solutions Inc C.BNXT

Alternate Symbol(s):  BNXTF

Healthcare
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (CSE:BNXT)

BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

Accesswire October 29, 2024

Terry Lynch Joins BioNxt as Capital Markets Advisor

Accesswire October 7, 2024

BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities

Accesswire September 26, 2024

BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

Accesswire September 9, 2024

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

Accesswire August 15, 2024

BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development

Accesswire July 17, 2024

BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization

Accesswire July 9, 2024

BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

Accesswire June 19, 2024

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Newsfile June 13, 2024
View More News ››

Opinion & Analysis (CSE:BNXT)

XPhyto: Buyouts, Biosensors and a Booming Business

Stockhouse Editorial August 4, 2021

XPhyto: Proof of Concept for Mescalin Synthesis

Stockhouse Editorial June 10, 2021

XPhyto Therapeutics: Are they Selling the Solution to Germany’s Rapid Testing Crisis?

Stockhouse Editorial June 3, 2021

A Life Sciences Project Accelerator Kicks into High Gear

Stockhouse Editorial May 11, 2021

XPhyto: Why Rapid PCR Testing is Here to Stay

Stockhouse Editorial April 23, 2021

XPhyto: Is Mescaline the Next Big Mood-Modifying Medicine?

Stockhouse Editorial April 6, 2021
View More Opinion ››

Bullboard Posts (CSE:BNXT)

BioNxt Receives Positive International Examination Report

VANCOUVER, BC / ACCESSWIRE / September 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT...
Betteryear2 - September 9, 2024

Testing tools markets seemingly getting a reaction again

The company is bouncing upward today on decent volume and trade numbers. Not sure where it is coming from though. Does anyone know? I don...
KidAtHeart - May 6, 2024

Toasted 101

We know what direction this stock is headed. Lot of potential back in the early covid days but now not so sure. GLTA and perhaps some...
Franman184 - July 25, 2022

XPhyto Announces Offering of Units of the Company

XPhyto Therapeutics Announces Offering of Units of the Company 2022-07-22 13:30 ET - News Release XPHY Close 2022-07-22 C$ 0.485 ...
toasted101 - July 22, 2022

RE:RE:Hello XPHY - ANYBODY OUT THERE!

Wow this stock is hurting !! 
RDtrade - April 28, 2022

XPhyto, Biosensors Market and Product Developments

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / April 11, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE...
Betteryear2 - April 11, 2022
View more Bullboard ››

Masivo Silver Corp.

Masivo Silver Corp.

Masivo Silver Corp. is a Canadian junior silver and gold mining exploration company based in Vancouver, Canada. The Company ...
View More »